PMID- 23158620 OWN - NLM STAT- MEDLINE DA - 20121119 DCOM- 20130122 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 67 IP - 6 DP - 2012 Dec TI - Pain and nonmelanoma skin cancer in transplant patients. PG - 1387-8 LID - 10.1016/j.jaad.2012.06.013 [doi] LID - S0190-9622(12)00674-3 [pii] FAU - Kwatra, Shawn G AU - Kwatra SG FAU - Mills, Kyle C AU - Mills KC FAU - Zeitany, Alex AU - Zeitany A FAU - Pearce, Daniel J AU - Pearce DJ FAU - Williford, Phillip M AU - Williford PM FAU - D'Agostino, Ralph B Jr AU - D'Agostino RB Jr FAU - Yosipovitch, Gil AU - Yosipovitch G LA - eng PT - Letter PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 SB - IM MH - Carcinoma, Basal Cell/*epidemiology MH - Carcinoma, Squamous Cell/*epidemiology MH - Humans MH - *Organ Transplantation MH - Pain/*epidemiology MH - Postoperative Complications/*epidemiology MH - Prospective Studies MH - Skin Neoplasms/*epidemiology EDAT- 2012/11/20 06:00 MHDA- 2013/01/23 06:00 CRDT- 2012/11/20 06:00 PHST- 2012/02/23 [received] PHST- 2012/05/18 [revised] PHST- 2012/06/04 [accepted] AID - S0190-9622(12)00674-3 [pii] AID - 10.1016/j.jaad.2012.06.013 [doi] PST - ppublish SO - J Am Acad Dermatol. 2012 Dec;67(6):1387-8. doi: 10.1016/j.jaad.2012.06.013. PMID- 23158619 OWN - NLM STAT- MEDLINE DA - 20121119 DCOM- 20130122 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 67 IP - 6 DP - 2012 Dec TI - Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses. PG - 1386-7 LID - 10.1016/j.jaad.2012.05.039 [doi] LID - S0190-9622(12)00669-X [pii] FAU - Bissonnette, Robert AU - Bissonnette R FAU - Bolduc, Chantal AU - Bolduc C FAU - Maari, Catherine AU - Maari C FAU - Nigen, Simon AU - Nigen S LA - eng PT - Letter PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 RN - 0 (Photosensitizing Agents) RN - 0 (methyl 5-aminolevulinate) RN - 106-60-5 (Aminolevulinic Acid) SB - IM MH - Aminolevulinic Acid/*analogs & derivatives/therapeutic use MH - Humans MH - Keratosis, Actinic/*drug therapy MH - Photochemotherapy/*methods MH - Photosensitizing Agents/*therapeutic use EDAT- 2012/11/20 06:00 MHDA- 2013/01/23 06:00 CRDT- 2012/11/20 06:00 PHST- 2012/04/12 [received] PHST- 2012/05/31 [accepted] AID - S0190-9622(12)00669-X [pii] AID - 10.1016/j.jaad.2012.05.039 [doi] PST - ppublish SO - J Am Acad Dermatol. 2012 Dec;67(6):1386-7. doi: 10.1016/j.jaad.2012.05.039. PMID- 23071148 OWN - NLM STAT- MEDLINE DA - 20121016 DCOM- 20130108 IS - 1540-8140 (Electronic) IS - 0021-9525 (Linking) VI - 199 IP - 2 DP - 2012 Oct 15 TI - Hedgehog pathway inhibition and the race against tumor evolution. PG - 193-7 LID - 10.1083/jcb.201207140 [doi] AB - Dependence of basal cell carcinomas and medulloblastomas on the Hedgehog pathway provides an opportunity for targeted or "personalized" therapy. The recent effectiveness and FDA approval of the first Smoothened inhibitors validates this class of agents, but has revealed drug-resistant tumor variants that bypass Smoothened inhibition. Here, we summarize the effectiveness of Hedgehog pathway inhibitors and highlight promising areas for the development of next generation drug antagonists for Hedgehog-dependent cancers. AD - Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. FAU - Atwood, Scott X AU - Atwood SX FAU - Chang, Anne Lynn S AU - Chang AL FAU - Oro, Anthony E AU - Oro AE LA - eng GR - R01AR046786/AR/NIAMS NIH HHS/United States GR - R01AR052785/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Cell Biol JT - The Journal of cell biology JID - 0375356 RN - 0 (Anilides) RN - 0 (Antineoplastic Agents) RN - 0 (GLI1 protein, human) RN - 0 (Hedgehog Proteins) RN - 0 (HhAntag691) RN - 0 (Pyridines) RN - 0 (Receptors, G-Protein-Coupled) RN - 0 (SMO protein, human) RN - 0 (Transcription Factors) RN - 0 (Veratrum Alkaloids) RN - ZH658AJ192 (cyclopamine) SB - IM MH - Anilides/pharmacology/therapeutic use MH - Antineoplastic Agents/therapeutic use MH - Carcinoma, Basal Cell/*drug therapy/metabolism MH - Cerebellar Neoplasms/drug therapy/metabolism MH - Drug Resistance, Neoplasm MH - Hedgehog Proteins/*antagonists & inhibitors/*metabolism MH - Humans MH - Medulloblastoma/*drug therapy/metabolism MH - Pyridines/pharmacology/therapeutic use MH - Receptors, G-Protein-Coupled/*antagonists & inhibitors MH - Signal Transduction/*drug effects MH - Skin Neoplasms/drug therapy/metabolism MH - Transcription Factors/antagonists & inhibitors MH - Veratrum Alkaloids/pharmacology/therapeutic use PMC - PMC3471227 OID - NLM: PMC3471227 EDAT- 2012/10/17 06:00 MHDA- 2013/01/09 06:00 CRDT- 2012/10/17 06:00 PMCR- 2013/04/15 00:00 AID - jcb.201207140 [pii] AID - 10.1083/jcb.201207140 [doi] PST - ppublish SO - J Cell Biol. 2012 Oct 15;199(2):193-7. doi: 10.1083/jcb.201207140. PMID- 22958088 OWN - NLM STAT- MEDLINE DA - 20121003 DCOM- 20130108 IS - 1524-4725 (Electronic) IS - 1076-0512 (Linking) VI - 38 IP - 10 DP - 2012 Oct TI - AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. PG - 1582-603 LID - 10.1111/j.1524-4725.2012.02574.x [doi] AB - The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics. This document reflects the rating of appropriateness of MMS for each of these clinical scenarios by a ratings panel in a process based on the appropriateness method developed by the RAND Corp (Santa Monica, CA)/University of California-Los Angeles (RAND/UCLA). At the conclusion of the rating process, consensus was reached for all 270 (100%) scenarios by the Ratings Panel, with 200 (74.07%) deemed as appropriate, 24 (8.89%) as uncertain, and 46 (17.04%) as inappropriate. For the 69 basal cell carcinoma scenarios, 53 were deemed appropriate, 6 uncertain, and 10 inappropriate. For the 143 squamous cell carcinoma scenarios, 102 were deemed appropriate, 7 uncertain, and 34 inappropriate. For the 12 lentigo maligna and melanoma in situ scenarios, 10 were deemed appropriate, 2 uncertain, and 0 inappropriate. For the 46 rare cutaneous malignancies scenarios, 35 were deemed appropriate, 9 uncertain, and 2 inappropriate. These appropriate use criteria have the potential to impact health care delivery, reimbursement policy, and physician decision making on patient selection for MMS, and aim to optimize the use of MMS for scenarios in which the expected clinical benefit is anticipated to be the greatest. In addition, recognition of those scenarios rated as uncertain facilitates an understanding of areas that would benefit from further research. Each clinical scenario identified in this document is crafted for the average patient and not the exception. Thus, the ultimate decision regarding the appropriateness of MMS should be determined by the expertise and clinical experience of the physician. CI - (c) 2012 by the American Society for Dermatologic Surgery, Inc., and the American Academy of Dermatology, Inc. Published by Wiley Periodicals, Inc. AD - Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA. CN - American Academy of Dermatology CN - American College of Mohs Surgery CN - American Society for Dermatologic Surgery Association CN - American Society for Mohs Surgery CN - Ad Hoc Task Force FAU - Connolly, Suzanne M AU - Connolly SM FAU - Baker, Diane R AU - Baker DR FAU - Coldiron, Brett M AU - Coldiron BM FAU - Fazio, Michael J AU - Fazio MJ FAU - Storrs, Paul A AU - Storrs PA FAU - Vidimos, Allison T AU - Vidimos AT FAU - Zalla, Mark J AU - Zalla MJ FAU - Brewer, Jerry D AU - Brewer JD FAU - Begolka, Wendy S AU - Begolka WS FAU - Berger, Timothy G AU - Berger TG FAU - Bigby, Michael AU - Bigby M FAU - Bolognia, Jean L AU - Bolognia JL FAU - Brodland, David G AU - Brodland DG FAU - Collins, Scott AU - Collins S FAU - Cronin, Terrence A Jr AU - Cronin TA Jr FAU - Dahl, Mark V AU - Dahl MV FAU - Grant-Kels, Jane M AU - Grant-Kels JM FAU - Hanke, C W AU - Hanke CW FAU - Hruza, George J AU - Hruza GJ FAU - James, William D AU - James WD FAU - Lober, Clifford W AU - Lober CW FAU - McBurney, Elizabeth I AU - McBurney EI FAU - Norton, Scott A AU - Norton SA FAU - Roenigk, Randall K AU - Roenigk RK FAU - Wheeland, Ronald G AU - Wheeland RG FAU - Wisco, Oliver J AU - Wisco OJ LA - eng PT - Consensus Development Conference PT - Journal Article PT - Practice Guideline DEP - 20120907 PL - United States TA - Dermatol Surg JT - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JID - 9504371 SB - IM CIN - Dermatol Surg. 2012 Oct;38(10):1581. PMID: 23030368 MH - Carcinoma, Basal Cell/*surgery MH - Carcinoma, Squamous Cell/*surgery MH - Humans MH - Melanoma/*surgery MH - Mohs Surgery/*standards MH - Skin Neoplasms/*surgery EDAT- 2012/09/11 06:00 MHDA- 2013/01/09 06:00 CRDT- 2012/09/11 06:00 PHST- 2012/09/07 [aheadofprint] AID - 10.1111/j.1524-4725.2012.02574.x [doi] PST - ppublish SO - Dermatol Surg. 2012 Oct;38(10):1582-603. doi: 10.1111/j.1524-4725.2012.02574.x. Epub 2012 Sep 7. PMID- 22958072 OWN - NLM STAT- MEDLINE DA - 20121003 DCOM- 20130108 IS - 1524-4725 (Electronic) IS - 1076-0512 (Linking) VI - 38 IP - 10 DP - 2012 Oct TI - Clinical value of paraffin sections in association with Mohs micrographic surgery for nonmelanoma skin cancers. PG - 1631-8 LID - 10.1111/j.1524-4725.2012.02570.x [doi] AB - BACKGROUND: During Mohs micrographic surgery (MMS), situations can arise in which paraffin sections may be used in conjunction with frozen sections. OBJECTIVE: To determine the clinical value of paraffin sections in association with MMS, including frequency, reasons, and information obtained. METHODS AND MATERIALS: Single-center retrospective cohort study at a cancer center. MMS cases for nonmelanoma skin cancers over a 5-year period in which paraffin sections were used were identified. Reasons for submitting paraffin sections were reviewed. Initial biopsy, Mohs frozen section, and paraffin section diagnoses and histologic subtypes were compared. RESULTS: In 258 (7.8%) cases, paraffin sections were used in association with MMS. The most common reasons were to further assess high-risk histologic features or unusual frozen section findings, to complete tumor staging of cutaneous squamous cell carcinomas, and to assess perineural invasion (PNI). Initial biopsy diagnosis differed from the Mohs frozen and paraffin section diagnoses in 20% to 22% of cases. The initial biopsy histologic subtype changed from low or indeterminate to high risk in Mohs frozen and paraffin sections in 24% to 29% of cases. CONCLUSION: In MMS for select high-risk or unusual nonmelanoma skin cancers, paraffin sections are useful in more accurately documenting tumor histology, completing cutaneous squamous cell carcinoma staging, and detecting PNI. CI - (c) 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc. AD - Preferred Health Partners, New York, Brooklyn, USA. FAU - Ebede, Tobechi L AU - Ebede TL FAU - Lee, Erica H AU - Lee EH FAU - Dusza, Stephen W AU - Dusza SW FAU - Busam, Klaus J AU - Busam KJ FAU - Nehal, Kishwer S AU - Nehal KS LA - eng PT - Journal Article DEP - 20120907 PL - United States TA - Dermatol Surg JT - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JID - 9504371 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Biopsy MH - Carcinoma, Basal Cell/*pathology/surgery MH - Carcinoma, Squamous Cell/*pathology/surgery MH - Chi-Square Distribution MH - Female MH - Frozen Sections MH - Humans MH - Male MH - Middle Aged MH - Paraffin Embedding MH - Peripheral Nervous System/pathology MH - Retrospective Studies MH - Skin/*pathology MH - Skin Neoplasms/*pathology/surgery MH - Young Adult EDAT- 2012/09/11 06:00 MHDA- 2013/01/09 06:00 CRDT- 2012/09/11 06:00 PHST- 2012/09/07 [aheadofprint] AID - 10.1111/j.1524-4725.2012.02570.x [doi] PST - ppublish SO - Dermatol Surg. 2012 Oct;38(10):1631-8. doi: 10.1111/j.1524-4725.2012.02570.x. Epub 2012 Sep 7. PMID- 22857860 OWN - NLM STAT- MEDLINE DA - 20120820 DCOM- 20130117 IS - 1879-0887 (Electronic) IS - 0167-8140 (Linking) VI - 104 IP - 2 DP - 2012 Aug TI - Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. PG - 263-6 LID - 10.1016/j.radonc.2012.06.013 [doi] AB - PURPOSE: To provide practice guidelines for delineating clinical target volume (CTV) for radiotherapy planning of non melanoma (NMSC) skin cancers. METHODS AND MATERIALS: A prospective, single arm, study. Preoperatively, a radiation oncologist outlined the boundary of a gross lesion, and drew 5-mm incremental marks in four directions from the delineated border. Under local anesthesia, the lesion was excised, and resection margins were assessed microscopically by frozen section. Once resection margins were clear, the microscopic tumor extent was calculated using the presurgical incremental markings as references. A potential relationship between the distance of microscopic tumor extension and other variables was analyzed. RESULTS: A total of 159 lesions in 150 consecutive patients, selected for surgical excision with frozen section assisted assessment of resection margins, were accrued. The distance of microscopic tumor extension beyond a gross lesion varied from 1mm to 15 mm, with a mean of 5.3mm. The microscopic tumor extent was positively correlated with the size of gross lesion, histology and number of surgical attempts required to obtain a clear margin. To provide a 95% or greater chance of covering microscopic disease we make the following recommendations for CTV margins; 10mm for BCC less than 2 cm, 13 mm for BCC greater than 2 cm, 11 mm for SCC less than 2 cm, and 14 mm for SCC greater than 2 cm. CONCLUSIONS: Tumors greater than 2 cm and SCC histology required larger margins to adequately cover the microscopic extent of disease. This information is crucial in radiation planning of NMSC. Clinicians should be cautioned, as these guidelines may not offer optimum treatment for patients with extremely large or small lesions. CI - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved. AD - University of Toronto, Ontario, Canada. FAU - Khan, Luluel AU - Khan L FAU - Choo, Richard AU - Choo R FAU - Breen, Dale AU - Breen D FAU - Assaad, Dalal AU - Assaad D FAU - Fialkov, Jefferey AU - Fialkov J FAU - Antonyshyn, Oleh AU - Antonyshyn O FAU - McKenzie, David AU - McKenzie D FAU - Woo, Tony AU - Woo T FAU - Zhang, Liying AU - Zhang L FAU - Barnes, Elizabeth AU - Barnes E LA - eng PT - Comparative Study PT - Journal Article DEP - 20120731 PL - Ireland TA - Radiother Oncol JT - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JID - 8407192 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Analysis of Variance MH - Carcinoma, Basal Cell/pathology/*radiotherapy/surgery MH - Carcinoma, Squamous Cell/pathology/*radiotherapy/surgery MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Frozen Sections MH - Humans MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasm Invasiveness/pathology MH - Neoplasm Staging MH - Neoplastic Cells, Circulating/pathology/radiation effects MH - *Practice Guidelines as Topic MH - Prospective Studies MH - Radiotherapy Planning, Computer-Assisted/*methods MH - Risk Assessment MH - Skin Neoplasms/*pathology/*radiotherapy/surgery MH - Treatment Outcome MH - Tumor Burden/radiation effects EDAT- 2012/08/04 06:00 MHDA- 2013/01/18 06:00 CRDT- 2012/08/04 06:00 PHST- 2011/11/29 [received] PHST- 2012/06/04 [revised] PHST- 2012/06/13 [accepted] PHST- 2012/07/31 [aheadofprint] AID - S0167-8140(12)00315-5 [pii] AID - 10.1016/j.radonc.2012.06.013 [doi] PST - ppublish SO - Radiother Oncol. 2012 Aug;104(2):263-6. doi: 10.1016/j.radonc.2012.06.013. Epub 2012 Jul 31. PMID- 22851213 OWN - NLM STAT- MEDLINE DA - 20120821 DCOM- 20121226 IS - 1096-9101 (Electronic) IS - 0196-8092 (Linking) VI - 44 IP - 7 DP - 2012 Sep TI - Long-term outcomes following Foscan(R)-PDT of basal cell carcinomas. PG - 533-40 LID - 10.1002/lsm.22056 [doi] AB - BACKGROUND AND OBJECTIVE: In a previous publication we showed that mTHPC-PDT (Foscan(R)-PDT) is an effective treatment of basal cell carcinomas (BCCs) in "difficult to treat" locations and presented optimized treatment parameters to reduce costs and side effects. Now we present long-term results of the same study population. STUDY DESIGN/MATERIALS AND METHODS: Following PDT of a total of 460 BCCs in 117 subjects, the patients/lesions were followed-up for a mean duration of 42 (range: 2-72) months. Two patients dropped out of follow-up; 13 patients died of unrelated causes. Recurrences were treated either by repeated PDT or other established methods. RESULTS: The sustained clearance rate was 93.7% and the overall treatment success rate was 90.7%. Kaplan-Meier analysis revealed an estimated recurrence free fraction of patients at 5 years of 95.1%, 92.4%, 85.1%, and 74.0% for the four different photosensitizer dose groups (0.06-0.15, 0.05, 0.04, and 0.03 mg/kg). High-risk lesions (recurrences, thickness >3 mm) recurred more often than low-risk ones, and recurrences mostly (>50%) occurred during the first year of follow-up. CONCLUSION: Long-term outcomes of high-dose (0.06-0.15 mg/kg) and reduced-dose (0.05 mg/kg) Foscan(R)-PDT in "difficult to treat" BCCs compare favorably with other methods, even in high-risk lesions (recurrent and/or thick lesions). A recommended combination of treatment parameters for low-dose therapy seems to be: 0.05 mg/kg Foscan(R), 24 hours drug-light interval (DLI), fluence >/=40 J/cm(2) . Prospective randomized studies are needed to look into low-dose mTHPC-PDT of BCCs in more detail and to directly compare it with other treatments. CI - Copyright (c) 2012 Wiley Periodicals, Inc. AD - Department of Otorhinolaryngology, Head & Neck Surgery, Klinikum Grosshadern at the Ludwig Maximilian University, Marchioninistr. 15, 81377 Munich, Germany. christian.betz@med.uni-muenchen.de FAU - Betz, Christian S AU - Betz CS FAU - Rauschning, Winrich AU - Rauschning W FAU - Stranadko, Evgueni Ph AU - Stranadko EP FAU - Riabov, Mikhail V AU - Riabov MV FAU - Volgin, Valery N AU - Volgin VN FAU - Albrecht, Volker AU - Albrecht V FAU - Nifantiev, Nikolay E AU - Nifantiev NE FAU - Hopper, Colin AU - Hopper C LA - eng PT - Evaluation Studies PT - Journal Article DEP - 20120731 PL - United States TA - Lasers Surg Med JT - Lasers in surgery and medicine JID - 8007168 RN - 0 (Mesoporphyrins) RN - 0 (Photosensitizing Agents) RN - FU21S769PF (temoporfin) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Basal Cell/*drug therapy/mortality MH - Drug Administration Schedule MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Lasers, Semiconductor MH - Male MH - Mesoporphyrins/*therapeutic use MH - Middle Aged MH - Neoplasm Recurrence, Local/therapy MH - Photochemotherapy/*methods MH - Photosensitizing Agents/*therapeutic use MH - Skin Neoplasms/*drug therapy/mortality MH - Treatment Outcome EDAT- 2012/08/02 06:00 MHDA- 2012/12/27 06:00 CRDT- 2012/08/02 06:00 PHST- 2012/07/06 [accepted] PHST- 2012/07/31 [aheadofprint] AID - 10.1002/lsm.22056 [doi] PST - ppublish SO - Lasers Surg Med. 2012 Sep;44(7):533-40. doi: 10.1002/lsm.22056. Epub 2012 Jul 31. PMID- 22841216 OWN - NLM STAT- MEDLINE DA - 20120730 DCOM- 20130103 IS - 1873-2623 (Electronic) IS - 0041-1345 (Linking) VI - 44 IP - 6 DP - 2012 Jul-Aug TI - Subsequent nonmelanoma skin cancer after liver transplantation. PG - 1568-70 LID - 10.1016/j.transproceed.2012.05.005 [doi] AB - BACKGROUND: Liver transplant recipients have a high risk of developing nonmelanoma skin cancer (NMSC). Some develop multiple NMSC. METHODS: Patients with a follow-up of >1 year have been prospectively followed to detect NMSC. We studied the risk of developing >1 NMSC. RESULTS: After a follow-up of 2658 patient-years (mean, 8.5 years per patient), 59/312 (19%) patients were diagnosed with NMSC. Twenty-five had >1 NMSC. The 5-year risk of developing 1 NMSC, >1 NMSC, and a subsequent NMSC (a new NMSC after a first one) were 15%, 5.5%, and 46.5%, respectively. Age >60 years and transplantation for hepatocellular carcinoma were independently associated with a higher risk of developing >1 NMSC. CONCLUSION: NMSC are frequent complications after liver transplantation and they may show a high rate of recurrence. Older age and hepatocellular carcinoma were related to the development of multiple NMSC. CI - Copyright (c) 2012 Elsevier Inc. All rights reserved. AD - Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, and the Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain. iherrero@unav.es FAU - Herrero, J I AU - Herrero JI FAU - Espana, A AU - Espana A FAU - D'Avola, D AU - D'Avola D FAU - Pardo, F AU - Pardo F FAU - Inarrairaegui, M AU - Inarrairaegui M FAU - Rotellar, F AU - Rotellar F FAU - Sangro, B AU - Sangro B FAU - Quiroga, J AU - Quiroga J LA - eng PT - Journal Article PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 SB - IM MH - Age Factors MH - Carcinoma, Basal Cell/*etiology MH - Carcinoma, Hepatocellular/surgery MH - Carcinoma, Squamous Cell/*etiology MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Liver Diseases/*surgery MH - Liver Neoplasms/surgery MH - Liver Transplantation/*adverse effects MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Neoplasms, Second Primary/*etiology MH - Proportional Hazards Models MH - Prospective Studies MH - Risk Assessment MH - Risk Factors MH - Sex Factors MH - Skin Neoplasms/*etiology MH - Spain MH - Time Factors MH - Treatment Outcome EDAT- 2012/07/31 06:00 MHDA- 2013/01/04 06:00 CRDT- 2012/07/31 06:00 AID - S0041-1345(12)00436-8 [pii] AID - 10.1016/j.transproceed.2012.05.005 [doi] PST - ppublish SO - Transplant Proc. 2012 Jul-Aug;44(6):1568-70. doi: 10.1016/j.transproceed.2012.05.005. PMID- 22818756 OWN - NLM STAT- MEDLINE DA - 20121119 DCOM- 20130122 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 67 IP - 6 DP - 2012 Dec TI - Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. PG - 1235-41 LID - 10.1016/j.jaad.2012.06.001 [doi] LID - S0190-9622(12)00625-1 [pii] AB - BACKGROUND: Effective nonsurgical modalities are limited in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). OBJECTIVE: We sought to evaluate the efficacy and viability of superficial x-ray therapy in the treatment of BCC and SCC in an outpatient setting. METHODS: A retrospective analysis was performed on 1715 histologically confirmed primary cutaneous BCC and SCC treated with superficial x-ray therapy at Dermatology Associates of Tallahassee in Florida between 2000 and 2010. RESULTS: Of the 1715 tumors reviewed during this period, 712 were histologically proven BCC (631 nodular and 81 superficial), 994 were SCC (861 SCC in situ and 133 invasive SCC), and 9 displayed distinct features of both BCC and SCC in the same biopsy specimen. Kaplan-Meier estimates (with 95% confidence intervals) of cumulative recurrence rates of all tumors at 2 and 5 years were 1.9% (1%-2.7%) and 5.0% (3.2%-6.7%), respectively; of BCC at 2 and 5 years were 2% (0.8%-3.3%) and 4.2% (1.9%-6.4%), respectively; and of all SCC at 2 and 5 years were 1.8% (0.8%-2.8%) and 5.8% (2.9%-8.7%), respectively. Tumors on male patients and those with a diameter greater than 2 cm were associated with a statistically significant increase in recurrence likelihood. LIMITATIONS: This study represents only patients treated in 1 dermatology office in North Florida and may not be representative of the general patient population. CONCLUSIONS: Superficial x-ray therapy remains a viable nonsurgical option for the treatment of primary BCC and SCC in patients where surgical intervention is declined, unadvisable, or potentially associated with significant cosmetic or functional limitations. CI - Copyright (c) 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. AD - Dermatology Associates of Tallahassee, Tallahassee, Florida 32308, USA. FAU - Cognetta, Armand B AU - Cognetta AB FAU - Howard, Brett M AU - Howard BM FAU - Heaton, Henry P AU - Heaton HP FAU - Stoddard, Earl R AU - Stoddard ER FAU - Hong, Hyokyoung Grace AU - Hong HG FAU - Green, W Harris AU - Green WH LA - eng PT - Journal Article DEP - 20120719 PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 SB - IM MH - Aged MH - Carcinoma, Basal Cell/*radiotherapy MH - Carcinoma, Squamous Cell/*radiotherapy MH - Female MH - Humans MH - Male MH - Patient Selection MH - Retrospective Studies MH - Skin Neoplasms/*radiotherapy EDAT- 2012/07/24 06:00 MHDA- 2013/01/23 06:00 CRDT- 2012/07/24 06:00 PHST- 2012/01/04 [received] PHST- 2012/05/25 [revised] PHST- 2012/06/05 [accepted] PHST- 2012/07/19 [aheadofprint] AID - S0190-9622(12)00625-1 [pii] AID - 10.1016/j.jaad.2012.06.001 [doi] PST - ppublish SO - J Am Acad Dermatol. 2012 Dec;67(6):1235-41. doi: 10.1016/j.jaad.2012.06.001. Epub 2012 Jul 19. PMID- 22810303 OWN - NLM STAT- MEDLINE DA - 20121016 DCOM- 20121226 IS - 1523-1747 (Electronic) IS - 0022-202X (Linking) VI - 132 IP - 11 DP - 2012 Nov TI - Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. PG - 2544-51 LID - 10.1038/jid.2012.227 [doi] AB - Basal cell carcinoma (BCC) is the most common cancer in the United States today, and patients who have had one are likely to have multiple carcinomas over time. Predictors of new BCCs on the face and ears among those at very high risk have not been studied in detail. We sought to do so prospectively in the context of a 6-year trial. We found that the number of BCCs in the prior 5 years was the most important predictor. Age, sun sensitivity, occupational sun exposure before the age of 30 years (but not afterward), lower educational level, history of eczema, the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and more sunscreen use in the week, but not the 6 months, before enrollment were also independent predictors, but sunburns, baseline sun exposure, and other sun-protective measures, other skin cancers, and actinic keratoses were not. None of the eczema patients had a history of topical calcineurin use. The cumulative risk of BCC was 55% at 5 years. These findings document the key risk factors in this very high-risk population, suggesting that the history of eczema may increase the risk in those at high risk and that early sun exposure is important even in this group, and underscoring the need for chemopreventive strategies. AD - Dermatoepidemiology Unit, VA Medical Center Providence, Providence, Rhode Island, USA. FAU - Dyer, Robert K AU - Dyer RK FAU - Weinstock, Martin A AU - Weinstock MA FAU - Cohen, Tobias S D AU - Cohen TS FAU - Rizzo, Amilcar E AU - Rizzo AE FAU - Bingham, Stephen F AU - Bingham SF CN - VATTC Trial Group LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20120719 PL - United States TA - J Invest Dermatol JT - The Journal of investigative dermatology JID - 0426720 RN - 0 (Antineoplastic Agents) RN - 0 (Sunscreening Agents) RN - 302-79-4 (Tretinoin) SB - IM CIN - J Invest Dermatol. 2012 Nov;132(11):2497-9. PMID: 23069907 MH - Administration, Topical MH - Adult MH - Aged MH - Aged, 80 and over MH - Antineoplastic Agents/administration & dosage MH - Carcinoma, Basal Cell/diagnosis/*epidemiology/*prevention & control MH - Eczema/epidemiology MH - Educational Status MH - Female MH - Follow-Up Studies MH - Humans MH - Kaplan-Meier Estimate MH - Keratosis, Actinic/epidemiology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Predictive Value of Tests MH - Risk Factors MH - Skin Neoplasms/diagnosis/*epidemiology/*prevention & control MH - Sunlight/adverse effects MH - Sunscreening Agents/therapeutic use MH - Tretinoin/*administration & dosage MH - Veterans/statistics & numerical data IR - Weinstock MA FIR - Weinstock, Martin A IR - Marcolivio K FIR - Marcolivio, Kimberly IR - Weinstock M FIR - Weinstock, Martin IR - Bingham S FIR - Bingham, Stephen IR - Point P FIR - Point, Perry IR - DiGiovanna J FIR - DiGiovanna, John IR - Hall R FIR - Hall, Russell IR - Naylor M FIR - Naylor, Mark IR - Taylor JR FIR - Taylor, J Richard IR - Vertree J FIR - Vertree, Julia IR - White C FIR - White, Clifton IR - Hall R FIR - Hall, Russell IR - Hannah D FIR - Hannah, Deborah IR - Eilers D FIR - Eilers, David IR - Liang T FIR - Liang, Tehming IR - Sakla N FIR - Sakla, Nadia IR - Kreuger A FIR - Kreuger, Ann IR - Cole G FIR - Cole, Gary IR - Jeffes E FIR - Jeffes, Edward IR - Labrador T FIR - Labrador, Terri IR - Taylor JR FIR - Taylor, J Richard IR - Kirsner R FIR - Kirsner, Robert IR - Kerri JE FIR - Kerri, Jonette E IR - Falabella AG FIR - Falabella, Anna G IR - Givens M FIR - Givens, Margarita IR - Naylor M FIR - Naylor, Mark IR - Benson MB FIR - Benson, Mary Beth IR - Perry L FIR - Perry, Lisa IR - Kalivas J FIR - Kalivas, James IR - Yanni C FIR - Yanni, Catherine IR - Targovnik S FIR - Targovnik, Selma IR - Austin J FIR - Austin, Janet IR - Collier S FIR - Collier, Susan IR - Collins JF FIR - Collins, Joseph F IR - Bingham S FIR - Bingham, Stephen IR - Calvert B FIR - Calvert, Beverly IR - Connor P FIR - Connor, Philip IR - Crigler C FIR - Crigler, Colleen IR - Davis D FIR - Davis, Dawn IR - Grubb P FIR - Grubb, Pat IR - Kelly J FIR - Kelly, Judy IR - Kirk G FIR - Kirk, Gail IR - Lawson K FIR - Lawson, Karen IR - Linzy L FIR - Linzy, Linda IR - Palmer L FIR - Palmer, Lorrine IR - Rhoads M FIR - Rhoads, Maxine IR - Sather M FIR - Sather, Mike IR - Copeland E FIR - Copeland, Erica IR - Fye C FIR - Fye, Carol IR - Gagne W FIR - Gagne, William IR - de Naranjo PG FIR - de Naranjo, Patricia Grimes IR - Messick C FIR - Messick, Chad IR - Vertrees J FIR - Vertrees, Julia IR - Piepkorn M FIR - Piepkorn, Michael IR - White C FIR - White, Clifton IR - Lew R FIR - Lew, Robert IR - Braverman I FIR - Braverman, Irwin IR - Cole B FIR - Cole, Bernard IR - Kalish R FIR - Kalish, Richard IR - McLean D FIR - McLean, David IR - Thiers B FIR - Thiers, Bruce EDAT- 2012/07/20 06:00 MHDA- 2012/12/27 06:00 CRDT- 2012/07/20 06:00 PHST- 2012/07/19 [aheadofprint] AID - jid2012227 [pii] AID - 10.1038/jid.2012.227 [doi] PST - ppublish SO - J Invest Dermatol. 2012 Nov;132(11):2544-51. doi: 10.1038/jid.2012.227. Epub 2012 Jul 19. PMID- 22808251 OWN - NLM STAT- MEDLINE DA - 20120718 DCOM- 20130110 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 7 DP - 2012 TI - Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients. PG - e40754 LID - 10.1371/journal.pone.0040754 [doi] AB - Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most frequent skin cancers in humans. An intact immune system is critical for protection against SCC since organ transplant recipients (OTR) have a 60- to 100-fold higher risk for developing these tumors. The role of the innate immune system in tumor immunosurveillance is unclear. Our aim was to determine the expression of selected innate immune genes in BCC and SCC arising in immunocompetent and OTR patients. Lesional and peri-lesional skin from 28 SCC and 19 BCC were evaluated for mRNA expression of toll-like receptors (TLR) 1-9, downstream TLR signaling molecules, and antimicrobial peptides. 11 SCC occurring in OTR patients were included in the analysis. We found that SCC but not BCC showed significantly elevated expression of TLRs 1-3, 5-8, TRIF and TRAF1. TNF was increased in SCC compared to normal skin. BCC showed increased IFNgamma. hBD1, hBD2 and psoriasin mRNA and protein expression were significantly higher in SCC than in normal skin and higher than in BCC. SCC from OTR showed only an increase in hBD2 but no increase in hBD1 or psoriasin. We conclude that innate immune gene expression in SCC is distinct from normal skin and BCC. BCC shows lesser induction of innate immune genes. SCC from OTR patients have depressed expression of hBD1 and psoriasin compared to SCC from immunocompetent patients. AD - Division of Dermatology, University of California San Diego, La Jolla, California, United States of America. FAU - Muehleisen, Beda AU - Muehleisen B FAU - Jiang, Shang Brian AU - Jiang SB FAU - Gladsjo, Julie A AU - Gladsjo JA FAU - Gerber, Monika AU - Gerber M FAU - Hata, Tissa AU - Hata T FAU - Gallo, Richard L AU - Gallo RL LA - eng GR - R01 AI052453/AI/NIAID NIH HHS/United States GR - R01 AI0833358/AI/NIAID NIH HHS/United States GR - R01 AR052728/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120713 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Antimicrobial Cationic Peptides) RN - 0 (Cytokines) RN - 0 (RNA, Messenger) RN - 0 (Toll-Like Receptors) SB - IM MH - Aged MH - Antimicrobial Cationic Peptides/genetics/metabolism MH - Carcinoma, Basal Cell/genetics/pathology MH - Carcinoma, Squamous Cell/genetics/pathology MH - Cell Differentiation/genetics MH - Cytokines/genetics/metabolism MH - Epidermis/pathology MH - Female MH - *Gene Expression Profiling MH - Gene Expression Regulation, Neoplastic MH - Genes, Neoplasm/genetics MH - Humans MH - Immunity, Innate/*genetics MH - Immunocompetence/*genetics/immunology MH - Immunocompromised Host/*genetics/immunology MH - Male MH - Melanoma/*genetics/immunology MH - Organ Transplantation MH - RNA, Messenger/genetics/metabolism MH - Signal Transduction/genetics MH - Skin Neoplasms/*genetics/*immunology MH - Toll-Like Receptors/genetics/metabolism PMC - PMC3396607 OID - NLM: PMC3396607 EDAT- 2012/07/19 06:00 MHDA- 2013/01/11 06:00 CRDT- 2012/07/19 06:00 PHST- 2012/03/29 [received] PHST- 2012/06/12 [accepted] PHST- 2012/07/13 [epublish] AID - 10.1371/journal.pone.0040754 [doi] AID - PONE-D-12-09225 [pii] PST - ppublish SO - PLoS One. 2012;7(7):e40754. doi: 10.1371/journal.pone.0040754. Epub 2012 Jul 13. PMID- 22772615 OWN - NLM STAT- MEDLINE DA - 20120709 DCOM- 20130118 IS - 0973-3922 (Electronic) IS - 0378-6323 (Linking) VI - 78 IP - 4 DP - 2012 Jul-Aug TI - Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients. PG - 448-53 LID - 10.4103/0378-6323.98075 [doi] AB - BACKGROUND: Organ transplant recipients (OTR) are at high risk of developing cutaneous neoplasms. Topical photodynamic therapy (PDT) has been used for the treatment of actinic keratosis (AK) in OTR. AIMS: The objective was to evaluate the efficacy of PDT with methylaminolevulinate (MAL) in the treatment of facial AK in OTR. As a secondary objective, we wanted to evaluate the usefulness of topical PDT in the reduction of photodamage in OTR. METHODS: A prospective, single center, single arm study was made. 16 OTR were included. Topical PDT was applied for 1 or 2 cycles depending on the patient's characteristics. An evaluation of AK was made at visits pre-treatment, at 12 weeks and at 24 weeks. Photodamage was measured with multispectral image technique (SkinCare). RESULTS: A complete response rate of 100% was achieved for AK in all patients; it persisted without change at 12 and 24 weeks of follow-up. 62.5% of patients improved their photodamage as measured by SkinCare(R), but this result was not statistically significant (P = 0.12). All patients had high level of satisfaction at the end of the therapy. CONCLUSIONS: MAL-PDT is an effective therapy for the treatment of AK in OTRs. It can reduce photodamage in this group of patients, but these results were not statistically significant. AD - Department of Dermatology, Pontificia Universidad Catolica de Chile, Chile. FAU - Hasson, Ariel AU - Hasson A FAU - Navarrete-Dechent, Cristian AU - Navarrete-Dechent C FAU - Nicklas, Claudia AU - Nicklas C FAU - de la Cruz, Claudia AU - de la Cruz C LA - eng PT - Clinical Trial PT - Journal Article PL - India TA - Indian J Dermatol Venereol Leprol JT - Indian journal of dermatology, venereology and leprology JID - 7701852 RN - 0 (Immunosuppressive Agents) RN - 0 (Photosensitizing Agents) RN - 0 (methyl 5-aminolevulinate) RN - 106-60-5 (Aminolevulinic Acid) SB - IM MH - Adult MH - Aged MH - Aminolevulinic Acid/*analogs & derivatives/pharmacology/therapeutic use MH - Carcinoma, Squamous Cell/chemically induced/prevention & control MH - Facial Dermatoses/drug therapy/pathology MH - Female MH - Humans MH - Immunosuppression/adverse effects MH - Immunosuppressive Agents/adverse effects MH - Keratosis, Actinic/*drug therapy/pathology MH - Male MH - Middle Aged MH - Organ Transplantation/adverse effects MH - Patient Satisfaction MH - *Photochemotherapy MH - Photosensitizing Agents/pharmacology/*therapeutic use MH - Precancerous Conditions/*drug therapy MH - Scalp Dermatoses/drug therapy/pathology MH - Skin Aging/*drug effects MH - Skin Neoplasms/chemically induced/prevention & control MH - Treatment Outcome MH - Young Adult EDAT- 2012/07/10 06:00 MHDA- 2013/01/19 06:00 CRDT- 2012/07/10 06:00 AID - ijdvl_2012_78_4_448_98075 [pii] AID - 10.4103/0378-6323.98075 [doi] PST - ppublish SO - Indian J Dermatol Venereol Leprol. 2012 Jul-Aug;78(4):448-53. doi: 10.4103/0378-6323.98075. PMID- 22731750 OWN - NLM STAT- MEDLINE DA - 20120820 DCOM- 20130117 IS - 1477-7819 (Electronic) IS - 1477-7819 (Linking) VI - 10 DP - 2012 TI - Cutaneous squamous cell carcinoma metastatic to parotid - analysis of prognostic factors and treatment outcome. PG - 117 LID - 10.1186/1477-7819-10-117 [doi] AB - BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) comprises 20% of all skin cancer of the head and neck. A minority will metastasize to regional parotid lymph nodes. This study evaluates the St Vincent's Hospital, Sydney experience between 1996 and 2006. METHODS: A retrospective review was performed of patients who were evaluated in our multidisciplinary head and neck clinic with metastatic cSCC to parotid, and all treatment and pathologic details were reviewed. Statistical analysis, including univariate and multivariate analyses, were performed using Cox proportional hazards regression mode, overall and disease-specific survival were estimated by the Kaplan-Meier method. RESULTS: Sixty-seven patients were identified. Some 90 % were male, and with a mean age of 72.8 years. One died on the first postoperative day. The remaining 66 patients received radiotherapy. For these 66 patients, the two-year and five-year overall survival rate was 0.83 and 0.72, respectively. The two-year and five-year disease-free survival rate was 0.91 and 0.83 respectively. Overall survival was only significantly correlated to the extent of parotidectomy (superficial versus total; P = 0.0256). Margin status was available in 59 patients. The only parameter that significantly correlated with disease-free survival was margin status (close/negative versus positive P = 0.0348). Other parameters of immune suppression, perineural invasion, extra capsular extension, degree of tumour differentiation, number of positive nodes, extent of neck dissection and radiotherapy dosage delivered did not confer prognostic significance. CONCLUSIONS: This study confirmed the association of adverse prognostic implication of positive margins on disease-free survival. Immune compromise was not a significant factor in this small group. Further studies are warranted in this population. AD - Faculty of Medicine, University of New South Wales, Botany Street, Sydney, NSW 2052, Australia. FAU - Goh, Robin Yeong Hong AU - Goh RY FAU - Bova, Ron AU - Bova R FAU - Fogarty, Gerald B AU - Fogarty GB LA - eng PT - Journal Article DEP - 20120625 PL - England TA - World J Surg Oncol JT - World journal of surgical oncology JID - 101170544 SB - IM MH - Aged MH - Carcinoma, Squamous Cell/mortality/*pathology/therapy MH - Combined Modality Therapy MH - Female MH - Follow-Up Studies MH - Humans MH - Lymphatic Metastasis MH - Male MH - Neoplasm Recurrence, Local/mortality/*pathology/therapy MH - Neoplasm Staging MH - Parotid Neoplasms/mortality/*secondary/therapy MH - Prognosis MH - Retrospective Studies MH - Skin Neoplasms/mortality/*pathology/therapy MH - Survival Rate PMC - PMC3422189 OID - NLM: PMC3422189 EDAT- 2012/06/27 06:00 MHDA- 2013/01/18 06:00 CRDT- 2012/06/27 06:00 PHST- 2012/01/22 [received] PHST- 2012/06/25 [accepted] PHST- 2012/06/25 [aheadofprint] AID - 1477-7819-10-117 [pii] AID - 10.1186/1477-7819-10-117 [doi] PST - epublish SO - World J Surg Oncol. 2012 Jun 25;10:117. doi: 10.1186/1477-7819-10-117. PMID- 22726224 OWN - NLM STAT- MEDLINE DA - 20120828 DCOM- 20130103 IS - 1755-148X (Electronic) IS - 1755-1471 (Linking) VI - 25 IP - 5 DP - 2012 Sep TI - Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. PG - 569-72 LID - 10.1111/j.1755-148X.2012.01031.x [doi] AB - B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival in patients with stage IV metastatic melanoma positive for the BRAF V600E mutation. However, the main drawback is the development of verrucal keratosis (hyperkeratotic papules with verruca-like characteristics with benign histological findings) and cutaneous squamous cell carcinomas (cuSCC). We have found upstream mutations in RAS as well as PIK3CA in both verrucal keratosis and cuSCC. This suggests that verrucal keratosis is an early clinical presentation of cuSCC in patients on BRAFi. CI - (c) 2012 John Wiley & Sons A/S. AD - Department of Dermatology, Westmead Hospital, Sydney, NSW, Australia. rachael.anforth@sydney.edu.au FAU - Anforth, Rachael AU - Anforth R FAU - Tembe, Varsha AU - Tembe V FAU - Blumetti, Tatiana AU - Blumetti T FAU - Fernandez-Penas, Pablo AU - Fernandez-Penas P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120806 PL - England TA - Pigment Cell Melanoma Res JT - Pigment cell & melanoma research JID - 101318927 RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.137 (PIK3CA protein, human) RN - EC 2.7.11.1 (BRAF protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) SB - IM MH - Base Sequence MH - Carcinoma, Squamous Cell/*chemically induced/enzymology/*genetics/pathology MH - DNA Mutational Analysis MH - Exons/genetics MH - Humans MH - Keratosis/*chemically induced/enzymology/genetics/pathology MH - Molecular Sequence Data MH - Phosphatidylinositol 3-Kinases/genetics MH - Protein Kinase Inhibitors/*adverse effects/pharmacology MH - Proto-Oncogene Proteins B-raf/*antagonists & inhibitors/metabolism MH - Skin Neoplasms/*chemically induced/enzymology/genetics/pathology MH - Warts/*chemically induced/enzymology/genetics/pathology EDAT- 2012/06/26 06:00 MHDA- 2013/01/04 06:00 CRDT- 2012/06/26 06:00 PHST- 2012/08/06 [aheadofprint] AID - 10.1111/j.1755-148X.2012.01031.x [doi] PST - ppublish SO - Pigment Cell Melanoma Res. 2012 Sep;25(5):569-72. doi: 10.1111/j.1755-148X.2012.01031.x. Epub 2012 Aug 6. PMID- 22723239 OWN - NLM STAT- MEDLINE DA - 20120622 DCOM- 20130108 IS - 1098-8793 (Electronic) IS - 0736-6825 (Linking) VI - 28 IP - 3 DP - 2012 Jun TI - Successes, revisions, and postoperative complications in 446 Mohs defect repairs. PG - 358-66 LID - 10.1055/s-0032-1312691 [doi] AB - OBJECTIVE: To determine factors predictive of complications and the need for adjunctive treatments repair of facial Mohs defects. METHODS: Charts of patients undergoing repair of facial defects from 2000 to 2010 in an academic facial plastic surgery practice were reviewed for patient medical history, tumor type, defect site and size, method of repair, postoperative sequelae, and adjunctive treatments. RESULTS: A total of 446 Mohs defect repairs were analyzed. Average patient age was 61.54 +/- 14.81 years. The average defect size was 17.55 +/- 10.48 mm. Overall complications were fairly uncommon and required intervention in only 18.74%; other than postoperative corticosteroid injections, additional procedures were necessary in only 6.95% of patients. Female sex; Fitzpatrick skin type 3; upper lip and nasal defects; glabellar, superiorly based nasolabial, bilobed, and rhombic flaps; and dermal suture extrusion were associated with increased complications. The most common complications seen were scar erythema and flap pincushioning. The most common revision techniques performed/recommended were selective laser photothermolysis (3.59%) and scar excision (3.59%). CONCLUSION: Repair of Mohs defects uncommonly requires adjunctive/revision techniques to reach satisfactory appearance. By understanding certain factors related to the patient, the defect, and the method of repair, surgeons can better choose reparative techniques and anticipate patient postoperative needs. CI - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. AD - Division of Facial Plastic Surgery, The New York Eye & Ear Infirmary, 310 E. 14th St., New York, NY 10003, USA. asclafani@nyee.edu FAU - Sclafani, Anthony P AU - Sclafani AP FAU - Sclafani, James A AU - Sclafani JA FAU - Sclafani, Anthony M AU - Sclafani AM LA - eng PT - Journal Article DEP - 20120621 PL - United States TA - Facial Plast Surg JT - Facial plastic surgery : FPS JID - 8405303 SB - D MH - Age Factors MH - Carcinoma, Basal Cell/surgery MH - Cicatrix/etiology MH - Erythema/etiology MH - Face/surgery MH - Facial Neoplasms/*surgery MH - Female MH - Follow-Up Studies MH - Humans MH - Laser Therapy MH - Lip Diseases/etiology MH - Male MH - Middle Aged MH - Mohs Surgery/*adverse effects/rehabilitation MH - Nose Diseases/etiology MH - Patient Satisfaction MH - *Postoperative Complications MH - Reconstructive Surgical Procedures/adverse effects/methods MH - Reoperation MH - Retrospective Studies MH - Risk Factors MH - Sex Factors MH - Surgical Flaps/classification/pathology MH - Suture Techniques/adverse effects MH - Treatment Outcome EDAT- 2012/06/23 06:00 MHDA- 2013/01/09 06:00 CRDT- 2012/06/23 06:00 PHST- 2012/06/21 [epublish] AID - 10.1055/s-0032-1312691 [doi] PST - ppublish SO - Facial Plast Surg. 2012 Jun;28(3):358-66. doi: 10.1055/s-0032-1312691. Epub 2012 Jun 21. PMID- 22718118 OWN - NLM STAT- MEDLINE DA - 20121016 DCOM- 20121226 IS - 1523-1747 (Electronic) IS - 0022-202X (Linking) VI - 132 IP - 11 DP - 2012 Nov TI - Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. PG - 2642-51 LID - 10.1038/jid.2012.190 [doi] AB - Squamous cell carcinomas (SCCs) are sun-induced skin cancers that are particularly numerous and aggressive in immunosuppressed individuals. SCCs evade immune detection at least in part by downregulating E-selectin on tumor vessels, thereby restricting entry of skin-homing T cells into tumors. We find that nitric oxide (NO) potently suppresses E-selectin expression on human endothelial cells and that SCCs are infiltrated by NO-producing iNOS(+) CD11b(+) CD33(+) CD11c(-) HLA-DR(-) myeloid-derived suppressor cells (MDSCs). MDSCs from SCCs produced NO, transforming growth factor-beta (TGF-beta), and arginase, and inhibited endothelial E-selectin expression in vitro. MDSCs from SCCs expressed the chemokine receptor CCR2 (chemokine (C-C motif) receptor 2) and tumors expressed the CCR2 ligand human beta-defensin 3 (HBD3), suggesting that CCR2/HBD3 interactions may contribute to MDSC recruitment to SCCs. Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction. Our results suggest that local production of NO in SCCs may impair vascular E-selectin expression. We show that MDSCs are critical producers of NO in SCCs and that NO inhibition restores vascular E-selectin expression, potentially enhancing T-cell recruitment. The iNOS inhibitors and other therapies that reduce NO production may therefore be effective in the treatment of SCCs and their premalignant precursor lesions, actinic keratoses. AD - Harvard Skin Disease Research Center and Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. FAU - Gehad, Ahmed E AU - Gehad AE FAU - Lichtman, Michael K AU - Lichtman MK FAU - Schmults, Chrysalyne D AU - Schmults CD FAU - Teague, Jessica E AU - Teague JE FAU - Calarese, Adam W AU - Calarese AW FAU - Jiang, Ying AU - Jiang Y FAU - Watanabe, Rei AU - Watanabe R FAU - Clark, Rachael A AU - Clark RA LA - eng GR - K08 AI060890/AI/NIAID NIH HHS/United States GR - P30 AR042689/AR/NIAMS NIH HHS/United States GR - P50 CA9368305/CA/NCI NIH HHS/United States GR - R01 AR056720/AR/NIAMS NIH HHS/United States GR - R01 AR056720/AR/NIAMS NIH HHS/United States GR - R03 MH095529/MH/NIMH NIH HHS/United States GR - R03 MH095529/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120621 PL - United States TA - J Invest Dermatol JT - The Journal of investigative dermatology JID - 0426720 RN - 0 (Antigens, CD11b) RN - 0 (Antigens, CD11c) RN - 0 (Antigens, Differentiation, T-Lymphocyte) RN - 0 (CCR2 protein, human) RN - 0 (CTAGE1 protein, human) RN - 0 (E-Selectin) RN - 0 (Enzyme Inhibitors) RN - 0 (HLA-DR Antigens) RN - 0 (ITGAM protein, human) RN - 0 (Membrane Glycoproteins) RN - 0 (Receptors, CCR2) RN - 10102-43-9 (Nitric Oxide) RN - 2149-70-4 (Nitroarginine) RN - EC 1.14.13.39 (NOS2 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 3.5.3.1 (Arginase) RN - EC 3.5.3.1 (arginase I, human) SB - IM MH - Antigens, CD11b/metabolism MH - Antigens, CD11c/metabolism MH - Antigens, Differentiation, T-Lymphocyte/metabolism MH - Arginase/genetics/metabolism MH - Carcinoma, Squamous Cell/genetics/*metabolism/pathology MH - Dermis/cytology MH - E-Selectin/genetics/*metabolism MH - Endothelial Cells/cytology/metabolism MH - Enzyme Inhibitors/pharmacology MH - Gene Expression Regulation, Neoplastic/physiology MH - HLA-DR Antigens/metabolism MH - Human Umbilical Vein Endothelial Cells MH - Humans MH - Membrane Glycoproteins/metabolism MH - Myeloid Cells/*metabolism/pathology MH - Nitric Oxide/*metabolism MH - Nitric Oxide Synthase Type II/antagonists & inhibitors/metabolism MH - Nitroarginine/pharmacology MH - Receptors, CCR2/genetics/metabolism MH - Skin Neoplasms/genetics/*metabolism/pathology MH - T-Lymphocytes/metabolism/pathology PMC - PMC3449043 MID - NIHMS374998 OID - NLM: NIHMS374998 OID - NLM: PMC3449043 EDAT- 2012/06/22 06:00 MHDA- 2012/12/27 06:00 CRDT- 2012/06/22 06:00 PMCR- 2013/05/01 00:00 PHST- 2012/06/21 [aheadofprint] AID - jid2012190 [pii] AID - 10.1038/jid.2012.190 [doi] PST - ppublish SO - J Invest Dermatol. 2012 Nov;132(11):2642-51. doi: 10.1038/jid.2012.190. Epub 2012 Jun 21. PMID- 22706476 OWN - NLM STAT- MEDLINE DA - 20120618 DCOM- 20130125 IS - 1349-3329 (Electronic) IS - 0040-8727 (Linking) VI - 227 IP - 2 DP - 2012 TI - Post-occlusive reactive hyperemia in basal cell carcinoma and its potential application to improve the efficacy of solid tumor therapies. PG - 139-47 AB - Tumor hypoxia is a hallmark of malignant tumors, and is a major factor in the resistance to anti-cancer therapies, particularly radiotherapy. Indeed, tumor blood flow often fluctuates, and thus the oxygen supply is often reduced, thereby inducing tumor hypoxia. We decided to explore whether post-occlusive reactive hyperemia, a physiological reaction known to occur in normal tissues, could be induced through a malignant tumor, basal cell carcinoma (BCC), in which angiogenesis occurs, as in all malignant tumors. Skin blood flow was measured in twelve patients with BCC, using Laser Speckle Contrast Imaging to determine BCC perfusion after three minutes of vascular occlusion, induced by limb tourniquet for limb tumors (4 BCC), and/or by clamping the pedicle of a skin flap with the BCC at its center, for other tumor locations (12 BCC). We demonstrated for the first time that post-occlusive reactive hyperemia occurs in malignant tumors in humans. BCC perfusion curves were similar to those of healthy skin, characterized by a peak of hyperemia after reperfusion followed by a progressive return to the pre-occlusion perfusion level. Induction of post-occlusive reactive hyperemia in malignant tumors is therefore a novel investigational approach that could lead to a new adjuvant tool to increase the efficacy of chemotherapy and radiotherapy, respectively through the synchronized temporary increase of tumor perfusion and oxygenation. AD - Department of Surgery, Institut Curie, Rene Huguenin Hospital, Saint-Cloud, France. julien.reyal@gmail.com FAU - Reyal, Julien AU - Reyal J FAU - Lebas, Nicolas AU - Lebas N FAU - Fourme, Emmanuelle AU - Fourme E FAU - Guihard, Thierry AU - Guihard T FAU - Vilmer, Catherine AU - Vilmer C FAU - Le Masurier, Perig AU - Le Masurier P LA - eng SI - ClinicalTrials.gov/NCT01455363 PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Japan TA - Tohoku J Exp Med JT - The Tohoku journal of experimental medicine JID - 0417355 RN - 137-58-6 (Lidocaine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anesthesia MH - Carcinoma, Basal Cell/*blood supply/pathology/physiopathology/*therapy MH - Female MH - Health MH - Humans MH - Hyperemia/*pathology/physiopathology MH - Laser-Doppler Flowmetry MH - Lidocaine/administration & dosage/pharmacology MH - Male MH - Middle Aged MH - Perfusion MH - Regression Analysis MH - Skin/blood supply/drug effects/physiopathology MH - Skin Neoplasms/*blood supply/pathology/physiopathology/*therapy MH - Treatment Outcome MH - Vasoconstriction/drug effects/*physiology MH - Vasodilation/drug effects EDAT- 2012/06/19 06:00 MHDA- 2013/01/26 06:00 CRDT- 2012/06/19 06:00 AID - DN/JST.JSTAGE/tjem/227.139 [pii] PST - ppublish SO - Tohoku J Exp Med. 2012;227(2):139-47. PMID- 22695101 OWN - NLM STAT- MEDLINE DA - 20121119 DCOM- 20130122 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 67 IP - 6 DP - 2012 Dec TI - Squamous cell carcinoma of the skin induces considerable sustained cost of care in organ transplant recipients. PG - 1242-9 LID - 10.1016/j.jaad.2012.03.033 [doi] LID - S0190-9622(12)00481-1 [pii] AB - BACKGROUND: Squamous cell carcinoma (SCC) is the most frequent cancer in organ transplant recipients (OTR). OBJECTIVE: We retrospectively analyzed the cost of dermatologic care in our OTR specialty clinic. METHODS: We collected billing data for OTR (n = 198) seen at the Dermatology Department of Zurich University Hospital over 4 years (2004-2007). Grouping by histology yielded the groups: SCC (n = 70), with SCC occurring within the observation period; past SCC (n = 40), with SCC before the observation period; in situ SCC (n = 13), when only in situ SCC had been diagnosed; biopsy negative (n = 49) for SCC and in situ SCC; and no biopsy ever (n = 26) within the observation period. RESULTS: Median annual costs for dermatologic care were US$1398 for SCC; US$776 for past SCC; US$308 for in situ SCC; US$211 for biopsy negative; and US$156 for no biopsy ever. Median cost per case of invasive SCC (US$1830) was higher than cost per case of in situ SCC (US$603). Regression analysis showed male sex (P = .006), age at transplantation (P = .001), and time since transplantation (P < .001) as independent cost factors. LIMITATIONS: This was an open, retrospective, single-center study with limited patient numbers. CONCLUSION: Dermatologic care for OTR is costly, and the majority of the costs are associated with SCC. Once SCC occurs, costs increase in a pronounced and sustained fashion. Interventions reducing the progression from in situ SCC to SCC could lead to considerable financial savings. We advocate sun protection, early diagnosis, and intervention to minimize the costs associated with SCC. CI - Copyright (c) 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. AD - Department of Dermatology, Zurich University Hospital, Zurich, Switzerland. FAU - Ruegg, Christian P AU - Ruegg CP FAU - Graf, Nicole AU - Graf N FAU - Muhleisen, Beda AU - Muhleisen B FAU - Szucs, Thomas D AU - Szucs TD FAU - French, Lars E AU - French LE FAU - Surber, Christian AU - Surber C FAU - Hofbauer, Gunther F L AU - Hofbauer GF LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120612 PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 SB - IM MH - Carcinoma, Squamous Cell/*economics/*therapy MH - Female MH - *Health Care Costs MH - Humans MH - Male MH - Middle Aged MH - *Organ Transplantation MH - Postoperative Complications/*economics/*therapy MH - Retrospective Studies MH - Skin Neoplasms/*economics/*therapy EDAT- 2012/06/15 06:00 MHDA- 2013/01/23 06:00 CRDT- 2012/06/15 06:00 PHST- 2011/10/17 [received] PHST- 2012/03/10 [revised] PHST- 2012/03/20 [accepted] PHST- 2012/06/12 [aheadofprint] AID - S0190-9622(12)00481-1 [pii] AID - 10.1016/j.jaad.2012.03.033 [doi] PST - ppublish SO - J Am Acad Dermatol. 2012 Dec;67(6):1242-9. doi: 10.1016/j.jaad.2012.03.033. Epub 2012 Jun 12. PMID- 22646842 OWN - NLM STAT- MEDLINE DA - 20121003 DCOM- 20130108 IS - 1524-4725 (Electronic) IS - 1076-0512 (Linking) VI - 38 IP - 10 DP - 2012 Oct TI - Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. PG - 1604-21 LID - 10.1111/j.1524-4725.2012.02452.x [doi] AB - BACKGROUND: Solid organ transplant recipients (SOTRs) have a 50 to 250 times greater risk of squamous cell carcinoma (SCC) than the general population and experience higher rates of invasive and metastatic disease. These greater risks are a product of the tumorigenic effects of their immunosuppressive medications. As the number of transplantations and the life expectancy of SOTRs increase, SCCs are becoming a major source of morbidity and mortality. OBJECTIVE: To present a practical approach for busy practicing clinicians to the care of SOTRs who are developing SCCs. Topics include assessment and treatment of new and neglected SOTRs; the dermatologist's role with the transplantation team; and practical considerations in the choice of topical agents, systemic agents, and immunosuppressive therapy manipulation. METHODS AND MATERIALS: An extensive literature search of the understanding of SCC pathophysiology and treatment in SOTRs was conducted. RESULTS: Presented here is a logical, concise guide to the care of SOTRs who are developing actinic keratoses and SCCs. CONCLUSION: Proper assessment of patients, understanding therapeutic alternatives and their application, and early institution of preventative and adjuvant therapies can help to decrease skin cancer-related morbidity and mortality in SOTRs. CI - (c) 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc. AD - Department of Dermatology, School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA. simonaritchie@hotmail.com FAU - Ritchie, Simon A AU - Ritchie SA FAU - Patel, Manisha J AU - Patel MJ FAU - Miller, Stanley J AU - Miller SJ LA - eng PT - Journal Article PT - Review DEP - 20120530 PL - United States TA - Dermatol Surg JT - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JID - 9504371 RN - 0 (Antineoplastic Agents) RN - 0 (Immunosuppressive Agents) SB - IM MH - Antineoplastic Agents/therapeutic use MH - Carcinoma, Squamous Cell/etiology/prevention & control/*therapy MH - Chemotherapy, Adjuvant MH - Humans MH - Immunosuppressive Agents/*adverse effects MH - Keratosis, Actinic/etiology/prevention & control/*therapy MH - Organ Transplantation/*adverse effects MH - Patient Care Team MH - Photochemotherapy MH - Skin Neoplasms/etiology/prevention & control/*therapy EDAT- 2012/06/01 06:00 MHDA- 2013/01/09 06:00 CRDT- 2012/06/01 06:00 PHST- 2012/05/30 [aheadofprint] AID - 10.1111/j.1524-4725.2012.02452.x [doi] PST - ppublish SO - Dermatol Surg. 2012 Oct;38(10):1604-21. doi: 10.1111/j.1524-4725.2012.02452.x. Epub 2012 May 30. PMID- 22607702 OWN - NLM STAT- MEDLINE DA - 20121026 DCOM- 20130117 IS - 1532-8392 (Electronic) IS - 0046-8177 (Linking) VI - 43 IP - 11 DP - 2012 Nov TI - Immunohistochemical and oncogenetic analyses of the esophageal basaloid squamous cell carcinoma in comparison with conventional squamous cell carcinomas. PG - 2012-23 LID - 10.1016/j.humpath.2012.02.010 [doi] LID - S0046-8177(12)00068-8 [pii] AB - Basaloid squamous cell carcinoma of the esophagus is a rare variant of squamous cell carcinoma. We reviewed 878 cases of esophageal squamous cell carcinoma and detected 22 cases (3%) of basaloid squamous cell carcinoma. These tumors and stage-matched paired conventional squamous cell carcinomas were investigated for clinicopathologic features and immunoreactivity of cytokeratin subtypes, p53, B-cell lymphoma 2 (bcl-2), beta-catenin, and epidermal growth factor receptor. Molecular aberrations in p53, CTNNB1 (the gene encoding beta-catenin), and epidermal growth factor receptor (EGFR) were also determined. Patients with basaloid squamous cell carcinomas demonstrated a 5-year survival rate of 42%, significantly worse than those with well-differentiated squamous cell carcinoma (P<.01). Histologically, solid nests with central necrosis and a cribriform pattern were identified in almost all (>/=95%) cases, and ductal differentiation was less frequent (45%) but associated with significantly better survival (P<.05). Compared with conventional squamous cell carcinomas, the basaloid squamous cell carcinomas were less immunoreactive for cytokeratin 14, cytokeratin 903, and membranous beta-catenin (P<.01-.001) but more reactive for bcl-2, nuclear beta-catenin, epidermal growth factor receptor, and Ki-67 (P<.05-.001). Direct sequencing showed mutations of p53 (36%), EGFR (14%), but not CTNNB1; fluorescent in situ hybridization detected amplification of the epidermal growth factor receptor gene (22%). In basaloid squamous cell carcinomas, low-level expression of cytokeratin 14/cytokeratin 903 and mutations of p53 and EGFR had a significant influence on worse survival (P<.05-.001). We conclude that the esophageal basaloid squamous cell carcinoma, a neoplasm with particularly aggressive biologic behavior, should be differentiated from conventional squamous cell carcinomas. In this context, immunohistochemical assessment of several markers might provide a useful adjunct diagnostic tool. Aberrations of p53 and epidermal growth factor receptor genes are possibly involved in progression of esophageal basaloid squamous cell carcinoma. CI - Copyright (c) 2012 Elsevier Inc. All rights reserved. AD - Department of Human Pathology, Juntendo University School of Medicine, Tokyo 113-8421, Japan. FAU - Imamhasan, Abdukadir AU - Imamhasan A FAU - Mitomi, Hiroyuki AU - Mitomi H FAU - Saito, Tsuyoshi AU - Saito T FAU - Hayashi, Takuo AU - Hayashi T FAU - Takahashi, Michiko AU - Takahashi M FAU - Kajiyama, Yoshiaki AU - Kajiyama Y FAU - Yao, Takashi AU - Yao T LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120518 PL - United States TA - Hum Pathol JT - Human pathology JID - 9421547 RN - 0 (DNA, Neoplasm) RN - 0 (Tumor Markers, Biological) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.10.1 (EGFR protein, human) RN - EC 2.7.10.1 (Receptor, Epidermal Growth Factor) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Basal Cell/genetics/metabolism/mortality/*pathology MH - Carcinoma, Squamous Cell/genetics/metabolism/mortality/*pathology MH - DNA Mutational Analysis MH - DNA, Neoplasm/analysis MH - Esophageal Neoplasms/genetics/metabolism/mortality/*pathology MH - Female MH - Gene Amplification MH - Humans MH - In Situ Hybridization, Fluorescence MH - Male MH - Middle Aged MH - Mutation MH - Receptor, Epidermal Growth Factor/genetics/metabolism MH - Survival Rate MH - Tumor Markers, Biological/genetics/metabolism MH - Tumor Suppressor Protein p53/genetics/metabolism EDAT- 2012/05/23 06:00 MHDA- 2013/01/18 06:00 CRDT- 2012/05/22 06:00 PHST- 2011/12/17 [received] PHST- 2012/02/10 [revised] PHST- 2012/02/15 [accepted] PHST- 2012/05/18 [aheadofprint] AID - S0046-8177(12)00068-8 [pii] AID - 10.1016/j.humpath.2012.02.010 [doi] PST - ppublish SO - Hum Pathol. 2012 Nov;43(11):2012-23. doi: 10.1016/j.humpath.2012.02.010. Epub 2012 May 18. PMID- 22512251 OWN - NLM STAT- MEDLINE DA - 20120724 DCOM- 20130102 LR - 20130219 IS - 1346-8138 (Electronic) IS - 0385-2407 (Linking) VI - 39 IP - 8 DP - 2012 Aug TI - Potential association of single nucleotide polymorphisms in pigmentation genes with the development of basal cell carcinoma. PG - 693-8 LID - 10.1111/j.1346-8138.2012.01559.x [doi] AB - The risk of developing skin cancers is dependent on a combination of environmental factors and personal genetic predispositions. Basal cell carcinoma (BCC) has been associated with single nucleotide polymorphisms in several pigmentation genes; however, there is still controversy concerning the mechanism by which these variants may increase the risk of BCC. The pathway may lead to pigmentation alone, but evidence for their independent influence is growing. Using a single base extension protocol, candidate polymorphisms within 11 known pigment-related genes were studied for their association with BCC in a population sample consisting of 164 patients and 707 controls. The significance of variation within the MC1R gene was confirmed and, in addition, position rs12203592 within the IRF4 gene was shown to be associated with BCC. These associations remained significant after adjustment for skin color. Gene-gene interactions were found to influence susceptibility to BCC. Among interacting genes are the two above-mentioned loci with main effect on BCC risk and additionally KITLG, TYRP1, ASIP and TYR. The obtained results indicate that polymorphism at MC1R and IRF4 constitute pigmentation-independent risk factor in the development of BCC. Moreover, susceptibility to BCC may be influenced by epistatic effects between pigmentation genes. CI - (c) 2012 Japanese Dermatological Association. AD - Department of Dermatology, Collegium Medicum of the Jagiellonian University, Krakow, Poland. FAU - Kosiniak-Kamysz, Agnieszka AU - Kosiniak-Kamysz A FAU - Pospiech, Ewelina AU - Pospiech E FAU - Wojas-Pelc, Anna AU - Wojas-Pelc A FAU - Marcinska, Magdalena AU - Marcinska M FAU - Branicki, Wojciech AU - Branicki W LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120418 PL - England TA - J Dermatol JT - The Journal of dermatology JID - 7600545 RN - 0 (ASIP protein, human) RN - 0 (Agouti Signaling Protein) RN - 0 (Interferon Regulatory Factors) RN - 0 (Membrane Glycoproteins) RN - 0 (Receptor, Melanocortin, Type 1) RN - 0 (Stem Cell Factor) RN - 0 (interferon regulatory factor-4) RN - EC 1.- (Oxidoreductases) RN - EC 1.14.18.- (TYRP1 protein, human) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Agouti Signaling Protein/genetics MH - Carcinoma, Basal Cell/epidemiology/*genetics MH - Epistasis, Genetic MH - Female MH - Genetic Association Studies/*statistics & numerical data MH - Genetic Predisposition to Disease/epidemiology MH - Humans MH - Incidence MH - Interferon Regulatory Factors/genetics MH - Male MH - Membrane Glycoproteins/genetics MH - Middle Aged MH - Oxidoreductases/genetics MH - Poland/epidemiology MH - *Polymorphism, Single Nucleotide MH - Receptor, Melanocortin, Type 1/genetics MH - Risk MH - Skin Neoplasms/epidemiology/*genetics MH - Skin Pigmentation/*genetics MH - Stem Cell Factor/genetics MH - Young Adult EDAT- 2012/04/20 06:00 MHDA- 2013/01/03 06:00 CRDT- 2012/04/20 06:00 PHST- 2012/04/18 [aheadofprint] AID - 10.1111/j.1346-8138.2012.01559.x [doi] PST - ppublish SO - J Dermatol. 2012 Aug;39(8):693-8. doi: 10.1111/j.1346-8138.2012.01559.x. Epub 2012 Apr 18. PMID- 22382344 OWN - NLM STAT- MEDLINE DA - 20120402 DCOM- 20130122 IS - 0315-162X (Print) IS - 0315-162X (Linking) VI - 39 IP - 4 DP - 2012 Apr TI - Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. PG - 712-5 LID - 10.3899/jrheum.110982 [doi] AB - OBJECTIVE: To assess the risk of total malignancy and nonmelanoma skin cancers (NMSC) in patients with rheumatoid arthritis (RA) receiving certolizumab and golimumab through a metaanalysis of data from randomized control trials (RCT). METHODS: We systematically reviewed the literature up to May 2011 in Medline databases, as well as abstracts from the 2009 and 2010 annual meetings of the European League Against Rheumatism and the American College of Rheumatology. Mantel-Haenszel method was used to determine a common odds ratio (OR). Statistical heterogeneity was assessed by chi-square Q test. We selected only RCT including more than 30 RA subjects randomly assigned to an anti-tumor necrosis factor (TNF) or a nonbiological disease-modifying antirheumatic drug (DMARD) control group. RESULTS: The literature search identified 793 articles; 6 (2 with certolizumab and 4 with golimumab) were selected for metaanalysis. A total of 2710 patients received at least 1 dose of certolizumab or golimumab. For anti-TNF-treated patients, 18 cancers (excluding NMSC) and 9 NMSC were observed versus 4 cases of total malignancy and 3 NMSC in control groups. Metaanalysis revealed a pooled OR of 1.06 (95% CI 0.39-2.85) for risk of total malignancy and 0.69 (95% CI 0.23-2.11) for risk of NMSC with certolizumab and golimumab versus DMARD. Heterogeneity was not significant. CONCLUSION: Metaanalysis of RCT of golimumab and certolizumab did not find an increased risk of total malignancy and NMSC. These results must be confirmed with longterm extension studies and registry studies, and careful monitoring remains mandatory. AD - Rheumatology Department, Lapeyronie Hospital, 371 avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France. FAU - LE Blay, Pierre AU - LE Blay P FAU - Mouterde, Gael AU - Mouterde G FAU - Barnetche, Thomas AU - Barnetche T FAU - Morel, Jacques AU - Morel J FAU - Combe, Bernard AU - Combe B LA - eng PT - Journal Article PT - Meta-Analysis PT - Review DEP - 20120301 PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Immunoglobulin Fab Fragments) RN - 0 (Polyethylene Glycols) RN - 0 (certolizumab pegol) RN - 0 (golimumab) SB - IM MH - Antibodies, Monoclonal/*adverse effects MH - Antibodies, Monoclonal, Humanized/*adverse effects MH - Carcinoma, Basal Cell/*epidemiology/immunology MH - Carcinoma, Squamous Cell/*epidemiology/immunology MH - Humans MH - Immunoglobulin Fab Fragments/*adverse effects MH - Polyethylene Glycols/*adverse effects MH - Skin Neoplasms/*epidemiology/immunology EDAT- 2012/03/03 06:00 MHDA- 2013/01/23 06:00 CRDT- 2012/03/03 06:00 PHST- 2012/03/01 [aheadofprint] AID - jrheum.110982 [pii] AID - 10.3899/jrheum.110982 [doi] PST - ppublish SO - J Rheumatol. 2012 Apr;39(4):712-5. doi: 10.3899/jrheum.110982. Epub 2012 Mar 1. PMID- 22285618 OWN - NLM STAT- MEDLINE DA - 20121015 DCOM- 20130117 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 67 IP - 5 DP - 2012 Nov TI - The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. PG - 829-35 LID - 10.1016/j.jaad.2012.01.010 [doi] LID - S0190-9622(12)00093-X [pii] AB - BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the most common malignancy after solid organ transplantation, with an increased risk of recurrence and metastasis over the general population. The newly updated 7th edition American Joint Committee on Cancer (AJCC) staging system for cSCC is based on consensus expert opinion and requires validation in large cohort studies and in specific patient subpopulations. OBJECTIVE: Our objective was to evaluate the risk of cSCC recurrence in a high-risk population of heart and lung transplant recipients, based on the 7th edition AJCC staging system. METHODS: We performed a 10-year retrospective cohort study of all primary cSCC diagnosed in heart and lung transplant recipients at a tertiary care academic dermatology center. RESULTS: The cumulative incidence of local recurrence was 4% for cSCC in situ and 19% for stage I cSCC at 5 years, and 54% for stage II cSCC at 3 years. Stage II tumors had a 10-fold greater risk of recurrence than stage I, and a 43-fold greater risk of recurrence than in situ tumors. LIMITATIONS: This study is limited to a specific patient subgroup at a tertiary care center, and may not be generalizable to all populations. CONCLUSIONS: Heart and lung transplant recipients are at high risk for local recurrence of cSCC. These data substantiate the prognostic accuracy of the newly updated 7th edition AJCC staging system for stage 0, I, and II cSCC in this population and demonstrate the aggressive behavior of this cancer in immunosuppressed patients. CI - Copyright (c) 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved. AD - Department of Dermatology, University of California at San Francisco, San Francisco, California 94115, USA. FAU - Metchnikoff, Christopher AU - Metchnikoff C FAU - Mully, Thaddeus AU - Mully T FAU - Singer, Jonathan P AU - Singer JP FAU - Golden, Jeffrey A AU - Golden JA FAU - Arron, Sarah T AU - Arron ST LA - eng GR - KL2 RR024130/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20120129 PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 SB - IM MH - Carcinoma, Squamous Cell/immunology/*pathology MH - *Heart Transplantation MH - Humans MH - Immunocompromised Host MH - Incidence MH - *Lung Transplantation MH - Neoplasm Recurrence, Local/immunology/*pathology MH - Neoplasm Staging MH - Postoperative Complications/immunology/*pathology MH - Prognosis MH - Proportional Hazards Models MH - Retrospective Studies MH - Skin Neoplasms PMC - PMC3345300 MID - NIHMS350368 OID - NLM: NIHMS350368 OID - NLM: PMC3345300 EDAT- 2012/01/31 06:00 MHDA- 2013/01/18 06:00 CRDT- 2012/01/31 06:00 PMCR- 2013/11/01 00:00 PHST- 2011/09/29 [received] PHST- 2011/12/15 [revised] PHST- 2012/01/12 [accepted] PHST- 2012/01/29 [aheadofprint] AID - S0190-9622(12)00093-X [pii] AID - 10.1016/j.jaad.2012.01.010 [doi] PST - ppublish SO - J Am Acad Dermatol. 2012 Nov;67(5):829-35. doi: 10.1016/j.jaad.2012.01.010. Epub 2012 Jan 29. PMID- 22025453 OWN - NLM STAT- MEDLINE DA - 20121019 DCOM- 20130107 IS - 1098-2744 (Electronic) IS - 0899-1987 (Linking) VI - 51 IP - 11 DP - 2012 Nov TI - Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. PG - 916-22 LID - 10.1002/mc.20861 [doi] AB - The microprocessor complex mediates intranuclear biogenesis of precursor microRNAs from the primary microRNA transcript. Extranuclear, mature microRNAs are incorporated into the RNA-induced silencing complex (RISC) before interaction with complementary target mRNA leads to transcriptional repression or cleavage. In this study, we investigated the expression profiles of the microprocessor complex subunit DiGeorge syndrome critical region gene 8 (DGCR8) and the RISC components argonaute-1 (AGO1), argonaute-2 (AGO2), as well as double-stranded RNA-binding proteins PACT, TARBP1, and TARBP2 in epithelial skin cancer and its premalignant stage. Patients with premalignant actinic keratoses (AK, n = 6), basal cell carcinomas (BCC, n = 15), and squamous cell carcinomas (SCC, n = 7) were included in the study. Punch biopsies were harvested from the center of the tumors (lesional), from healthy skin sites (intraindividual controls), and from healthy skin sites in a healthy control group (n = 16; interindividual control). The DGCR8, AGO1, AGO2, PACT, TARBP1, and TARBP2 mRNA expression levels were detected by quantitative real-time reverse transcriptase polymerase chain reaction. The DGCR8, AGO1, AGO2, PACT, and TARBP1 expression levels were significantly higher in the AK, BCC, and SCC groups than the healthy controls (P < 0.05). There was no significant difference in the TARBP2 expression levels between groups (P > 0.05). This study indicates that major components of the miRNA pathway, such as the microprocessor complex and RISC, are dysregulated in epithelial skin cancer. CI - Copyright (c) 2011 Wiley Periodicals, Inc. AD - Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany. FAU - Sand, Michael AU - Sand M FAU - Skrygan, Marina AU - Skrygan M FAU - Georgas, Dimitrios AU - Georgas D FAU - Arenz, Christoph AU - Arenz C FAU - Gambichler, Thilo AU - Gambichler T FAU - Sand, Daniel AU - Sand D FAU - Altmeyer, Peter AU - Altmeyer P FAU - Bechara, Falk G AU - Bechara FG LA - eng SI - ClinicalTrials.gov/NCT01345760 PT - Clinical Trial PT - Journal Article DEP - 20111024 PL - United States TA - Mol Carcinog JT - Molecular carcinogenesis JID - 8811105 RN - 0 (Argonaute Proteins) RN - 0 (DGCR8 protein, human) RN - 0 (MicroRNAs) RN - 0 (Nuclear Proteins) RN - 0 (PRKRA protein, human) RN - 0 (Proteins) RN - 0 (RNA-Binding Proteins) RN - 0 (RNA-Induced Silencing Complex) RN - 0 (TARBP1 protein, human) RN - 136628-24-5 (trans-activation responsive RNA-binding protein) SB - IM MH - Aged MH - Argonaute Proteins/*genetics MH - Carcinoma/*genetics MH - Carcinoma, Basal Cell/genetics MH - Carcinoma, Squamous Cell/genetics MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Keratosis, Actinic/*genetics MH - Male MH - MicroRNAs/genetics MH - Nuclear Proteins/*genetics MH - Proteins/*genetics MH - RNA-Binding Proteins/*genetics MH - RNA-Induced Silencing Complex/genetics MH - Skin/metabolism MH - Skin Neoplasms/*genetics EDAT- 2011/10/26 06:00 MHDA- 2013/01/08 06:00 CRDT- 2011/10/26 06:00 PHST- 2011/05/13 [received] PHST- 2011/08/14 [revised] PHST- 2011/09/09 [accepted] PHST- 2011/10/24 [aheadofprint] AID - 10.1002/mc.20861 [doi] PST - ppublish SO - Mol Carcinog. 2012 Nov;51(11):916-22. doi: 10.1002/mc.20861. Epub 2011 Oct 24.